Navigation Links
NASDAQ Grants Cell Therapeutics 180-Day Extension to Regain Compliance With Minimum Bid Price Rule
Date:11/2/2010

SEATTLE, Nov. 3, 2010 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) today announced that The NASDAQ Stock Market ("NASDAQ") has granted CTI an additional 180 days to regain compliance with NASDAQ's $1.00 minimum bid price rule under NASDAQ Marketplace Rule 5550(a)(2)). Previously, on May 3, 2010, CTI was notified by NASDAQ that CTI did not meet the minimum bid price rule required for continued listing and was provided until November 1, 2010 to achieve compliance.

CTI may achieve compliance during the 180-day period if the closing bid price of CTI's common stock is at least a $1.00 per share for a minimum of 10 consecutive business days before May 2, 2011.

About Cell Therapeutics, Inc.Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site, http://www.CellTherapeutics.com/investors_alert

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the market price of CTI's securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and that CTI may not regain compliance with the NASDAQ's minimum bid price rule by May 2, 2011, and CTI's ability to continue to raise capital as needed to fund its operations, competitive factors, technological developments, costs of developing, producing and selling pixantrone, and the risk factors listed or described from time to time in CTI
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Sigma-Aldrich (Nasdaq: SIAL) Declares Quarterly Dividend
2. XTL Biopharmaceuticals Receives Notice of Non-Compliance with Nasdaq Marketplace Rule Due to Changes in Board Composition
3. Oncothyreon announces receipt of notice of non-compliance with market value of listed securities standard for listing on The NASDAQ Global Market
4. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
5. TorreyPines Therapeutics Receives NASDAQ Deficiency Notice
6. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
7. China Sky One Medical, Inc. Approved to List on the NASDAQ Global Market
8. CTI Receives NASDAQ Letter
9. Micromet, Inc. Fills Audit Committee Vacancy and Regains Compliance With NASDAQ Marketplace Rule
10. Oncothyreon announces receipt of NASDAQ letter regarding compliance with NASDAQ Global Market listing standards
11. Neurobiological Technologies, Inc. (Nasdaq: NTII) Q4/08 Review Issued by Scimitar Equity, LLC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015  CytRx Corporation ... development company specializing in oncology, today announced positive ... trial with aldoxorubicin for the treatment of unresectable ... cancer.  The open-label, multisite trial is designed to ... in patients whose tumors have progressed following prior ...
(Date:5/21/2015)... King of Prussia, PA (PRWEB) May 21, 2015 ... that Julia O’Neill has joined the firm as senior ... more than 30 years of experience in the management ... the vaccines, biologics, pharmaceutical and chemical industries. , “We’re ... enhance our longstanding capabilities in data analytics,” said Dr. ...
(Date:5/20/2015)... MECHANICSBURG, Pa. , May 20, 2015 /PRNewswire/ ... announced that the Federal Trade Commission granted early ... (HSR) Antitrust Improvements Act of 1976, as amended, ... by MJ Acquisition Corporation, a joint venture that ... XII, L.P. As previously announced, MJ ...
(Date:5/20/2015)... BRAINTREE, Mass. , May 20, 2015  Haemonetics ... Brian Concannon , President & CEO, will present at ... New York on June 1 st , ... public may access Mr. Concannon,s presentation live via webcast ... Haemonetics Haemonetics (NYSE: HAE ) is a ...
Breaking Biology Technology:CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 2CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 3CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 4CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 5CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 6CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer) 7Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Select Medical Corporation's Proposed Acquisition of Concentra Inc. through Joint Venture with Welsh Carson Receives Antitrust Clearance 2
... , The statement below is from Pete Nicholas, Chairman ... employees and its Board of Directors. , , ... remarkably broad spectrum of issues. Foremost among them was his long and ... , He was a tireless advocate for patients, rights and for ...
... , , , ... molecular testing solutions, announced today that the company has been invited ... Conference, which is being held from September 9-11, 2009 at the ... Kureshy, CEO & President will provide an overview of the company ...
... NEW YORK, Aug. 26 /PRNewswire-Asia-FirstCall/ -- American Oriental,Bioengineering, ... or "AOBO"), a pharmaceutical,company dedicated to improving health ... range of prescription and over the counter ("OTC"),products, ... have been included in,China,s Essential Drug List ("EDL"). ...
Cached Biology Technology:Boston Scientific Statement on the Passing of Senator Edward Kennedy 2AOBO's Products Included in China's Essential Drug List 2
(Date:5/11/2015)... , May 11, 2015  Through a well-rounded UAS delegation ... had a strong showing at AUVSI,s Unmanned 2015 conference ... of Ohio,s UAS industry met with ... from all points along the UAS ecosystem. ... (DDC) Vice President for Aerospace Rich Knoll . "If ...
(Date:5/8/2015)... SAN JOSE, Calif. , May 8, 2015 ... human interface solutions, today announced that members of the executive ... J.P. Morgan 43rd Annual Technology, Media and Telecom Conference ... Westin Waterfront Hotel in Boston, MA ... Date: May 27, 2015 Time: 2:45pm ET Location: The New ...
(Date:5/5/2015)... 5, 2015, NXT-ID, Inc. (NASDAQ: NXTD ) ... the growing mobile commerce market, reminds investors and media that ... is presenting  at CARTES SECURE CONNEXIONS AMERICA 2015, held in ... The three-day conference is organized into a series ... is themed Global Fraud: Where is the Trust in ...
Breaking Biology News(10 mins):Ohio Flies High at Unmanned '15, Sets Stage for Ohio UAS Conference 2Synaptics to Present at Upcoming Investor Conferences 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 2NXT-ID, Inc.'s CTO, David Tunnell, Presents at CARTES SECURE CONNEXIONS AMERICA 2015 Today in Washington DC. 3
... CHICAGO, FEB. 4, 2010 New evidence that genetics ... explain why a woman can do everything right and still ... the 30th Annual Society for Maternal-Fetal Medicine (SMFM) meeting -- ... the mother and the fetus can make them susceptible to ...
... , , BLUE BELL, Pa. , ... ) today announced that its Mexican subsidiary has been awarded ... (Mexican Ministry of Internal Affairs/National Citizen Registry) to create and ... project would create a database with iris, fingerprint and facial ...
... Medical College of Georgia researchers are seeking to refine ... in Chinese medicine. Celastrol, derived from trees and ... China to treat symptoms such as fever, chills, joint ... also play a role in cancer treatment by inactivating ...
Cached Biology News:New research shows genes of pregnant women and their fetuses can increase the risk of preterm labor 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 2Unisys Awarded Contract to Provide Advanced Biometric Citizen Identification Solution to Government of Mexico 3Plant derivative could help refine cancer treatment 2
... generation of the popular precision current ... iontophoresis of neural transport tracers such ... amino acids into neural tissue, is ... also be used to make small ...
... The thermostable dUTPase(pyrococcus fruriosus) maximizes the ... DNA polymerases). It removes contaminating ... dNTP solutions. The presence of ... reaction can prevent dUTP misincorporation by ...
... The FLUOstar OPTIMA is a fully ... for life science labs in academia ... different measurement principles: Fluorescence Intensity ... Time-Resolved Fluorescence including DELFIATM ...
... The kit measures mitochondria intactness and ... membrane potential. Features and Benefits: ... for staining isolated mitochondria and for ... all the reagents required for the ...
Biology Products: